App Note: FDA-Accepted Monoclonality Assurance on the Beacon® Optofluidic System for Cell Line Development
Learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Related Resources
View All ResourcesApp Note: Bring Product Quality Assessment into Early Clone Selection with the Opto™ Assure Aggregation Assay
Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.
Webinar: Leveraging Innovative Technologies to Accelerate Biologics Development
At the 2021 BPS EU virtual conference, Beacon user Joaquina Mascarenhas, PhD, at Thermo Fisher Scientific shares how the Berkeley Lights Platform enables their cell line development to move at world class speed and select the best clones.
Webinar: Get More Molecules to The Clinic Faster
Watch our presentation from BPI Digital Week, hosted by Renee Tobias, to hear how our customers are using the Opto™ CLD workflow to find the best cell lines with the most confident monoclonality in just a few day and de-risk their path to IND faster.